Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) said it closed a previously announced underwritten offering of 10,309,280 common shares at US$4.85 each, raising US$50 million in gross proceeds. Cantor and Barclays were joint bookrunners; Bloom Burton and Lucid were lead managers. Net proceeds will fund Phase 3 HLP003 (MDD) with data expected in Q4 2026, plus HLP004 and HLP005, and for working capital.
How this was made
The 30-second read
Why it matters
Closing the offering at $4.85/share provides immediate capital and runway for Phase 3/Phase 2 development, but it also introduces dilution risk that can weigh on the stock until investors price in the new share supply.
Market read
A completed equity financing with explicit use of proceeds is a tradable catalyst for HELP, balancing dilution concerns against reduced financing overhang.
What to watch
The article doesn’t state net proceeds, share count post-raise, or any underwriting discount beyond the commission; those details can materially affect dilution expectations and near-term trading.
Background
Helus Pharma (commercial operating name of Cybin Inc.) is a clinical-stage CNS drug developer with NSAs including HLP003 (Phase 3) and HLP004/HLP005 (earlier stages).
Ticker impact
Helus Pharma (HELP) closed a $50M underwritten offering at $4.85/share, detailing proceeds use for Phase 3/Phase 2 programs and working capital.
Near-term pressure from dilution risk is likely, partially offset by reduced financing overhang tied to HLP003 Phase 3 APPROACH timing.
A $50M gross raise at a stated offering price is concrete and time-sensitive; however, the article provides no incremental clinical data, so the fundamental upside is indirect via runway.
Market effects
Adds to the ongoing biotech financing narrative; may influence sentiment toward clinical-stage CNS drug developers reliant on capital markets.
Primarily US-listed microcap/small-cap biotech flow; limited direct cross-sector read-across.
Low—specific to one issuer’s capital raise and CNS pipeline funding.
Counterpoint
The raise could be viewed as de-risking the funding path to HLP003 Phase 3 APPROACH (Q4 2026), reducing probability of future dilutive financings.
Key entities
- companyHelus Pharma
Closed a $50M underwritten common share offering; plans to fund HLP003 Phase 3 APPROACH (Q4 2026) and other programs.
- financial_advisorsCantor and Barclays
Joint bookrunning managers for the offering.
